Vaxcyte (PCVX) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Vaxcyte (PCVX) has outperformed Repligen (RGEN) over the past year, gaining 59.9% versus a gain of 14.6%. Over five years, PCVX leads with a +174.3% price change compared with -37.4% for RGEN. Repligen is the larger company by market cap ($10.62 billion vs $9.96 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCVX | RGEN |
|---|---|---|
| Share price | $66.96 | $167.22 |
| Market cap | $9.96B | $10.62B |
| 1-day change | +0.39% | -4.37% |
| YTD return | +45.12% | +2.05% |
| 1-year return | +59.92% | +14.59% |
| 5-year return | +174.31% | -37.35% |
| P/E ratio (TTM) | — | 229.07 |
| Forward P/E | — | 63.12 |
| EPS (TTM) | $-7.62 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $738.26M |
| Revenue growth (YoY) | — | +16.36% |
| Net income (latest FY) | $-766.63M | $48.89M |
| Gross margin | — | 52.32% |
| Operating margin | — | 7.47% |
| Net margin | — | 6.62% |
| 52-week high | $90.75 | $198.87 |
| 52-week low | $39.87 | $100.99 |
| Distance from 52-week high | -26.21% | -15.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.59% | +16.58% |
| Average volume | 1.50M | 1.14M |
| Shares outstanding | 148.81M | 63.49M |
| Employees | 507 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCVX has outperformed RGEN by 45.3 percentage points over the past year.
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
PCVX vs RGEN FAQ
Which is bigger, Vaxcyte or Repligen?
Repligen (RGEN) is larger, with a market capitalization of $10.62B compared with $9.96B for Vaxcyte (PCVX).
Which stock has performed better over the past year, PCVX or RGEN?
PCVX returned +59.92% over the past 12 months, compared with +14.59% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Vaxcyte and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.